Nerve block for pain alongside cancer drugs in advanced bile duct or pancreatic cancer
Observes a nerve block plus standard cancer drugs in advanced bile duct or pancreatic cancer.
Plain-language title generated from the registry record
Registry title: A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced bile duct or pancreatic cancer who have cancer pain. They will get a celiac plexus nerve block and then first-line cancer drugs.
- Sex
- All sexes can join.
- Disease stage
- Advanced bile duct (biliary tract) or pancreatic cancer, confirmed by tissue examination.
- Earlier treatment
- No earlier celiac plexus neurolysis or ablation. Planned to start a first-line systemic treatment (for example a PD-1/PD-L1 inhibitor alone or with chemotherapy or targeted therapy).
Main reasons for not taking part
- Earlier celiac plexus neurolysis or ablation
- Blood clotting problems (INR > 1.5, platelet count < 50 × 10⁹/L)
- Severe heart, liver or kidney failure (Child-Pugh Class C, eGFR < 30 mL/min, NYHA Class III-IV heart failure)
- Reasons the nerve block cannot be done, such as local infection or a different body structure
- Any condition that the investigator thinks makes joining unsafe
Read by machine on 13 November 2026.
Where in China
- Tongji HospitalWuhan, ChinaContact: Yang Dr. Wu, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT07326137
- Record updated
- 11 February 2026
- Original description
This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs.Read full original descriptionShow less
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade in Patients With Advanced Biliopancreatic Malignancies and Cancer-Related Pain
This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs.
Patients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes.
The goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.
Inclusion: Histologically confirmed advanced biliopancreatic malignancy (including biliary tract cancer or pancreatic cancer); Cancer-related pain: Baseline Numeric Rating Scale (NRS) pain score ≥ 4 points for over 1 week, with plans to receive celiac plexus neurolysis (CPN); Scheduled to receive a first-line systemic treatment regimen (e.g., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy/targeted therapy); ECOG Performance Status of 0-2 and an estimated life expectancy of ≥ 3 months.
Exclusion: Previous history of celiac plexus neurolysis or ablation; Contraindications to celiac plexus block (e.g., local infection, anatomical variation); Any other condition that, in the investigator's judgment, would preclude safe participation in the study; Coagulation disorders (INR > 1.5, platelet count < 50 × 10⁹/L); Severe cardiac, hepatic, or renal insufficiency (Child-Pugh Class C, estimated glomerular filtration rate (eGFR) < 30 mL/min, NYHA Class III-IV heart failure).